Alterations in energy balance following exenatide administration

Applied Physiology, Nutrition and Metabolism

Volumn 37, Issue 5, 2012, Pages 893-899

  Bradley, David P ^a   Kulstad, Roger ^b   Racine, Natalie ^c   Shenker, Yoram ^c   Meredith, Melissa ^c   Schoeller, Dale A ^c  

^a WASHINGTON UNIVERSITY   (United States)

^b MARSHFIELD CLINIC   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Doubly labeled water; Energy expenditure; Exenatide; Weight loss

Indexed keywords

ANTIDIABETIC AGENT; ANTIOBESITY AGENT; DRUG DERIVATIVE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; VENOM;

ADIPOSE TISSUE; ADULT; ALGORITHM; ARTICLE; BODY COMPOSITION; BODY MASS; CALORIC INTAKE; CLINICAL TRIAL; DRUG EFFECT; ENERGY METABOLISM; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; OBESITY; PATHOLOGY; PATIENT; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; ALGORITHMS; ANTI-OBESITY AGENTS; BODY COMPOSITION; BODY MASS INDEX; ENERGY INTAKE; ENERGY METABOLISM; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; PATIENT DROPOUTS; PEPTIDES; VENOMS; WEIGHT LOSS;

EID: 84865251381     PISSN: 17155312     EISSN: 17155320     Source Type: Journal    
DOI: 10.1139/H2012-068     Document Type: Article

References (23)

1. Barnett, A.H., Burger, J., Johns, D., Brodows, R., Kendall, D.M., Roberts, A., and Trautmann, M.E. 2007. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin. Ther. 29(11): 2333-2348. doi:10.1016/j.clinthera.2007.11.006. PMID:18158075.
2. Blonde, L., Klein, E.J., Han, J., Zhang, B., Mac, S.M., Poon, T.H., et al. 2006. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. 8 (4): 436-447. doi:10.1111/j.1463-1326.2006.00602.x. PMID: 16776751.
3. Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S., and Baron, A.D.Exenatide-113 Clinical Study Group. 2004. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 27(11): 2628-2635. doi:10.2337/diacare.27.11.2628. PMID: 15504997.
4. Davis, S.N., Johns, D., Maggs, D., Xu, H., Northrup, J.H., and Brodows, R.G. 2007. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care, 30(11): 2767-2772. doi:10.2337/dc06-2532. PMID:17595353.
5. DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S., and Baron, A.D. 2005. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes mellitus. Diabetes Care, 28(5): 1092-1100. doi:10.2337/diacare.28.5.1092. PMID:15855572.
6. Edwards, C.M., Stanley, S.A., Davis, R., Brynes, A.E., Frost, G.S., Seal, L.J., et al. 2001. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab. 281(1): E155-E161. PMID: 11404233.
7. Flint, A., Raben, A., Rehfeld, J.F., Holst, J.J., and Astrup, A. 2000. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int. J. Obes. Relat. Metab. Disord. 24(3): 288-298. doi:10.1038/sj.ijo.0801126. PMID: 10757621.
8. Flint, A., Raben, A., Ersbøll, A.K., Holst, J.J., and Astrup, A. 2001. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obes. Relat. Metab. Disord. 25(6): 781-792. doi:10. 1038/sj.ijo.0801627. PMID:11439290.
9. Heine, R.J., Van Gaal, L.F., Johns, D., Mihm, M.J., Widel, M.H., and Brodows, R.G.GWAA Study Group. 2005. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med. 143(8): 559-569. PMID:16230722.
10. International Diabetes Federation. 2011. Facts and figures. Available from www.idf.org. [Accessed 28 November 2011.]
11. Kendall, D.M., Riddle, M.C., Rosenstock, J., Zhuang, D., Kim, D.D., Fineman, M.S., and Baron, A.D. 2005. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 28(5): 1083-1091. doi:10.2337/diacare.28.5.1083. PMID:15855571.
12. Leibel, R.L., Rosenbaum, M., and Hirsch, J. 1995. Changes in energy expenditure resulting from altered body weight. N. Engl. J. Med. 332(10): 621-628. doi:10.1056/NEJM199503093321001. PMID: 7632212.
13. Nauck, M.A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., et al. 2007. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority study. Diabetologia, 50(2): 259-267. doi:10.1007/ s00125-006-0510-2. PMID:17160407.
14. Pannacciulli, N., Bunt, J.C., Koska, J., Bogardus, C., and Krakoff, J.J. 2006. Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am. J. Clin. Nutr. 84(3): 556-560. PMID:16960169.
15. Riddle, M.C., Henry, R.R., Poon, T.H., Zhang, B., Mac, S.M., Holcombe, J.H., et al. 2006. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab. Res. Rev. 22(6): 483-491. doi:10.1002/dmrr.646.PMID:16634116.
16. Schoeller, D.A. 1995. Limitations in the assessment of dietary energy intake by self-report. Metabolism, 44(2 Suppl. 2): 18-22. doi:10. 1016/0026-0495(95)90204-X. PMID:7869932.
17. Schoeller, D.A. 2002. Validation of habitual energy intake. Public Health Nutr. 5(5 6A): 883-888. doi:10.1079/PHN2002378. PMID: 12633511.
18. Schrocchi, L.A., Brown, T.J., Maclusky, N., Brubaker, P.L., Auerbach, A.B., Joyner, A.L., and Drucker, D.J. 1996. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2(11): 1254-1258. doi:10.1038/nm1196-1254. PMID:8898756.
19. Shalev, A., Holst, J.J., and Keller, U. 1997. Effects of glucagon-like peptide 1 (7-26 amide) on whole-body protein metabolism in healthy man. Eur. J. Clin. Invest. 27(1): 10-16. doi:10.1046/j. 1365-2362.1997.540613.x. PMID:9041371.
20. Subar, A.F., Kipnis, V., Troiano, R.P., Midthune, D., Schoeller, D.A., Bingham, S., et al. 2003. Using intake biomarkers to evaluate the extent of dietary misreporting in a large sample of adults: the OPEN study. Am. J. Epidemiol. 158(1): 1-13. doi:10.1093/aje/ kwg092.PMID:12835280.
21. Thorsen, T., Shriver, T., Racine, N., Richman, B.A., and Schoeller, D.A. 2011. Doubly labeled water analysis using cavity ring-down spectroscopy. Rapid Commun. Mass Spectrom. 25(1): 3-8. doi:10.1002/rcm.4795. PMID:21154648.
22. Verdich, C., Flint, A., Gutzwiller, J.P., Näslund, E., Beglinger, C., Hellström, P.M., et al. 2001. A meta-analysis of the effect of glucagon-like peptide-1 amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 86(9): 4382-4389. doi:10. 1210/jc.86.9.4382.PMID:11549680.
23. Zinman, B., Hoogwerf, B.J., Durán García, S., Milton, D.R., Giaconia, J.M., Kim, D.D., et al. 2007. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med. 146(7): 477-485. PMID:17404349.